Annals of internal medicine
-
Randomized Controlled Trial Multicenter Study
Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among CYP2C19 Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial.
Evidence on the risk-benefit ratio of dual antiplatelet therapies among patients with stroke and impaired renal function is limited and inconsistent. ⋯ Ministry of Science and Technology of the People's Republic of China.
-
Comment Randomized Controlled Trial Multicenter Study Pragmatic Clinical Trial
In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome.
Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.
-
Randomized Controlled Trial Multicenter Study
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. ⋯ National Institutes of Health.
-
Multicenter Study Clinical Trial
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. ⋯ Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
-
The Canadian Syncope Risk Score (CSRS) was developed to predict 30-day serious outcomes not evident during emergency department (ED) evaluation. ⋯ Swiss National Science Foundation & Swiss Heart Foundation.